Abstract
The pandemic has affected millions of people, and the associated chronic diseases can have prognostic and therapeutic consequences. One of the major chronic conditions is undoubtedly diabetes mellitus (DM), as it affects hospitalization and mortality. Currently, about half a billion people worldwide suffer from diabetes, and their number will increase by 25% and 51% in 2030 and 2045, respectively. The prevalence of pathology is projected to increase by 9.3% (463 million people): to 10.2% in 2030 and 10.9% in 2045. According to various studies, the prevalence of diabetes in patients with COVID‑19 fluctuated from
5% to 36%. Diabetes mellitus is one of the most serious comorbidities in patients with COVID‑19, which determines the relevance of the study of all aspects related to the relationship between these two diseases in both pathophysiological and therapeutic perspectives.
References
2. Rothan H.A. The epidemiology and pathogenesis of coronavirus disease (COVID‑19) outbreak / H.A. Rothan, S.N. Byrareddy // J. Autoimmun. — 2020. — Vol. 109. — P. 102433.
3. COVID‑19 and diabetes mellitus: the link and clinical implications / Chidiebere V. Ugwueze, Basil Chukwuma Ezeokpo, Bede I. Nnolim [et al.] // Dubai Diabetes Endocrinol. J. — 2020. — Vol. 26. — P. 69-77.
4. Chan-Yeung M. SARS: epidemiology / M. Chan-Yeung, R.H. Xu // Respirology. — 2003. — Vol. 8, Suppl. 1. — P. S9-S14.
5. From SARS to MERS, thrusting coronaviruses into the spotlight / Z. Song, Y. Xu, L. Bao [et al.] // Viruses. — 2019. — Vol. 11, № 1. — P. E59. 6. Poutanen S.M. Etiologic agents of infectious diseases. In: Long SS, editor. Principles and practice of paediatric infectious diseases. 4th ed. — 2012. — P. 1547-1712.
7. https://www.ecdc.europa.eu/en/geographical-distribution‑2019-ncov-cases
8. The lancet commission on diabetes: using data to transform diabetes care and patient lives / J.C. Chan, L.L. Lim, N.J. Wareham [et al.] // Lancet. — 2021. — Vol. 396, № 10267. — P. 2019-2082.
9. Parohan M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID‑19) infection: a systematic review and meta-analysis of observational studies / M. Parohan, S. Yaghoubi, A. Seraji [et al.] // Aging Male. — 2020. — Vol. 23, № 5. — P. 1416-1424.
10. The clinical characteristics and outcomes of COVID‑19 infections in patients with diabetes at a tertiary care center in the UAE / K. Hafidh, S. Abbas, A. Khan [et al.] // Dubai Diabetes Endocrinol. J. — 2021. — Vol. 26, № 4. — P. 1-6.
11. Diabetes mellitus and COVID‑19: associations and possible mechanisms / G. Li, Z. Chen, Z. Lv [et al.] // Int. J. Endocrinol. — 2021. — Vol. 2021. — P. 7394378.
12. Association of blood glucose control and outcomes in patients with COVID‑19 and pre-existing type 2 diabetes / L. Zhu, Z.G. She, X. Cheng [et al.] // Cell. Metab. — 2020. — Vol. 31, № 6. — P. 1068-1077.e3.
13. Prevalence of comorbidities and its effects in patients infected with SARS-CoV‑2: a systematic review and meta-analysis / J. Yang, Y. Zheng, X. Gou [et al.] // Int. J. Infect. Dis. — 2020. — Vol. 94. — P. 91-95.
14. Wu Z. Characteristics of and important lessons from the coronavirus disease 2019 (COVID‑19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention / Z. Wu, J.M. McGoogan // JAMA. — 2020. — Vol. 323, № 13. — P. 1239-1242.
15. Clinical characteristics of coronavirus disease 2019 in China / W. Guan, Z. Ni, Yu Hu [et al.] // N. Engl. J. Med. — 2020. — Vol. 382, № 18. — P. 1708-1720.